Grifols, S.A. Sponsored ADR Class B Stock News

Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial reported on Wednesday, citing unidentified industry sources.

Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Grifols' valuation is attractive, with a potential ...

Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost more than 30% of its market value.

Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7% sales growth.

Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9% Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9%

BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to identify plasma-based biomarkers that could indicate a person's likelihood of developing Parkinson's diseas...

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols.

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Spanish National Securities Market Commission (the “CNMV”) calling the CNMV's attention to the troubling and value destructive lack of ...